Skip to main content
SpringerLink
Log in

Gene Therapy Approaches for Lung Cancer

  • Chapter
Book cover Molecular Pathology of Lung Diseases

Part of the book series: Molecular Pathology Library ((MPLB,volume 1))

  • 2107 Accesses

Abstract

Lung cancers exhibit multiple genetic lesions that can be detected even in histologically normal bronchial mucosa from individuals with a smoking history. These genetic abnormalities provide an array of targets for therapy. Tobacco smoke has over 100 carcinogenic agents, and the specific interactions of specific carcinogens with genes that suppress tumors and repair DNA have been identified.1 Dysfunctional tumor suppressor genes are the most common genetic lesions identified to date in human lung cancers. Functional copies of tumor suppressor genes can be introduced into cancer cells by gene transfer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Denissenko MF, Pao A, Tang M, et al. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in p53. Science 1996;274(5286):430–432.

    Article  CAS  PubMed  Google Scholar 

  2. Burns T, El-Deiry W. The p53 pathway and apoptosis. J Cell Physiol 1999;181:231–239.

    Article  CAS  PubMed  Google Scholar 

  3. Fujiwara T, Grimm EA, Mukhopadhyay T, et al. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res 1993;53(18):4129–4133.

    CAS  PubMed  Google Scholar 

  4. Raycroft L, Wu H, Lozano G. Transcriptional activation by wild-type but not transforming mutants of the p53 antioncogene. Science 1990;249:1049–1051.

    Article  CAS  PubMed  Google Scholar 

  5. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998;281(5381):1322–1326.

    Article  CAS  PubMed  Google Scholar 

  6. Kamijo T, Zindy F, Roussel MF, et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997;91(5):649–659.

    Article  CAS  PubMed  Google Scholar 

  7. Isobe T, Hiyama K, Yoshida Y, et al. Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection. Jpn J Cancer Res 1994;85:1240–1246.

    CAS  PubMed  Google Scholar 

  8. Quinlan DC, Davidson AG, Summers CL, et al. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 1992;52:4828–4831.

    CAS  PubMed  Google Scholar 

  9. Martin HM, Filipe MI, Morris RW, et al. p53 expression and prognosis in gastric carcinoma. Int J Cancer 1992;50(6):859–862.

    Article  CAS  PubMed  Google Scholar 

  10. Cai DW, Mukhopadhyay T, Roth JA. A novel ribozyme for modification of mutated p53 pre-mRNA in non-small cell lung cancer cell lines. 3rd Antisense Workshop, November 13, 1993.

    Google Scholar 

  11. Zhang WW, Fang X, Mazur W, et al. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther 1994;1(1):5–13.

    PubMed  Google Scholar 

  12. Fujiwara T, Cai DW, Georges RN, et al. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model [commentary]. J Natl Cancer Inst 1994;86(19):1437–1438.

    Article  Google Scholar 

  13. Wang JX, Bucana CD, Roth JA, et al. Apoptosis induced in human osteosarcoma cells is one of the mechanisms for the cytocidal effect of Ad5CMV-p53. Cancer Gene Ther 1995;2(1):9–17.

    CAS  PubMed  Google Scholar 

  14. Georges RN, Mukhopadhyay T, Zhang Y, et al. Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct. Cancer Res 1993;53(8):1743–1746.

    CAS  PubMed  Google Scholar 

  15. Spitz FR, Nguyen D, Skibber J, et al. Adenoviral mediated p53 gene therapy enhances radiation sensitivity of colorectal cancer cell lines. Proc Am Assoc Cancer Res 1996;37:347.

    Google Scholar 

  16. Nielsen LL, Dell J, Maxwell E, et al. Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. Cancer Gene Ther 1997;4(2):129–138.

    CAS  PubMed  Google Scholar 

  17. Bouvet M, Fang B, Ekmekcioglu S, et al. Suppression of the immune response to an adenovirus vector and enhancement of intratumoral transgene expression by low-dose etoposide. Gene Ther 1998;5:189–195.

    Article  CAS  PubMed  Google Scholar 

  18. Xu M, Kumar D, Srinivas S, et al. Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity. Hum Gene Ther 1997;8:177–185.

    Article  CAS  PubMed  Google Scholar 

  19. Cusack JC, Spitz FR, Nguyen D, et al. High levels of gene transduction in human lung tumors following intralesional injection of recombinant adenovirus. Cancer Gene Ther 1996;3(4):245–249.

    CAS  PubMed  Google Scholar 

  20. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of human bax gene. Cell 1995;80(2):293–299.

    Article  CAS  PubMed  Google Scholar 

  21. Dameron KM, Volpert OV, Tainsky MA, et al. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994;265:1582–1584.

    Article  CAS  PubMed  Google Scholar 

  22. Molinier-Frenkel V, Le Boulaire C, Le Gal FA, et al. Longitudinal follow-up of cellular and humoral immunity induced by recombinant adenovirus-mediated gene therapy in cancer patients. Human Gene Ther 2000;11(13):1911–1920.

    Article  CAS  Google Scholar 

  23. Yen N, Ioannides CG, Xu K, et al. Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumor injection of an adenovirus vector expressing wild-type p53 (Ad-p53). Cancer Gene Ther 2000;7(4):530–536.

    Article  CAS  PubMed  Google Scholar 

  24. Carroll JL, Nielsen LL, Pruett SB, et al. The role of natural killer cells in adenovirus-mediated p53 gene therapy. Mol Cancer Ther 2001;1:49–60.

    CAS  PubMed  Google Scholar 

  25. Owen-Schaub LB, Zhang W, Cusack JC, et al. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 1995;15(6):3032–3040.

    CAS  PubMed  Google Scholar 

  26. Roth JA, Nguyen D, Lawrence DD, et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996;2(9):985–991.

    Article  CAS  PubMed  Google Scholar 

  27. Roth JA. Clinical Protocol: Modification of mutant K-ras gene expression in non-small cell lung cancer (NSCLC). Hum Gene Ther 1996;7(7):875–889.

    Article  CAS  PubMed  Google Scholar 

  28. Roth JA. Clinical Protocol: Modification of tumor suppressor gene expression and induction of apoptosis in non-small cell lung cancer (NSCLC) with an adenovirus vector expressing wildtype p53 and cisplatin. Hum Gene Ther 1996;7(8):1013–1030.

    Article  CAS  PubMed  Google Scholar 

  29. Swisher SG, Roth JA, Nemunaitis J, et al. Adenovirus-mediated p53 gene transfer in advanced non-small cell lung cancer. J Natl Cancer Inst 1999;91(9):763–771.

    Article  CAS  PubMed  Google Scholar 

  30. Yver A, Dreiling LK, Mohanty S, et al. Tolerance and safety of RPR/INGN 201, an adeno-viral vector containing a p53 gene, administered intratumorally in 309 patients with advanced cancer enrolled in phase I and II studies worldwide. Proc Am Soc Clin Oncol 1999;19:460a.

    Google Scholar 

  31. Yonish-Rouach E, Resnitzky D, Lotem J, et al. Wildtype p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature 1991;352(6333):345–347.

    Article  CAS  PubMed  Google Scholar 

  32. Ramqvist T, Magnusson KP, Wang Y, et al. Wild-type p53 induces apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53. Oncogene 1993;8:1495–1500.

    CAS  PubMed  Google Scholar 

  33. Shaw P, Bovey R, Tardy S, et al. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 1992;89(10):4495–4499.

    Article  CAS  PubMed  Google Scholar 

  34. Dewey WC, Ling CC, Meyn RE. Radiation induced apoptosis: relevance to radiotherapy. Int J Radiat Oncol Biol Phys 1995;33:781–796.

    CAS  PubMed  Google Scholar 

  35. Roth JA. Review: Clinical protocol for modification of tumor suppressor gene expression and induction of apoptosis in non-small cell lung cancer (NSCLC) with an adenovirus vector expressing wildtype p53 and cisplatin. Hum Gene Ther 1995;6(2):252–255.

    Google Scholar 

  36. Meyn RE, Stephens LC, Hunter NR, et al. Apoptosis in murine tumors treated with chemotherapy agents. Anticancer Drugs 1997;6:443–450.

    Article  Google Scholar 

  37. Fujiwara T, Grimm EA, Mukhopadhyay T, et al. Induction of chemosensitivity in human cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Surgical Forum 1994;45:524–526.

    Google Scholar 

  38. Nguyen DM, Spitz FR, Yen N, et al. Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. J Thorac Cardiovasc Surg 1996;112(5):1372–1377.

    Article  CAS  PubMed  Google Scholar 

  39. Hamada M, Fujiwara T, Hizuta A, et al. The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers. J Cancer Res Clin Oncol 1996;122(6):360–365.

    Article  CAS  PubMed  Google Scholar 

  40. Nguyen D, Spitz F, Kataoka M, et al. Enhancement of gene transduction in human carcinoma cells by DNA-damaging agents. Proc Am Assoc Cancer Res 1996;37:347.

    Google Scholar 

  41. Jasty R, Lu J, Irwin T, et al. Role of p53 in the regulation of irradiation-induced apoptosis in neuroblastoma cells. Mol Genet Metab 1998;65(2):155–164.

    Article  CAS  PubMed  Google Scholar 

  42. Akimoto T, Hunter NR, Buchmiller L, et al. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 1999;5(10):2884–2890.

    CAS  PubMed  Google Scholar 

  43. Feinmesser M, Halpern M, Fenig E, et al. Expression of the apoptosis-related oncogenes bcl-2, bax, and p53 in Merkel cell carcinoma: can they predict treatment response and clinical outcome? Hum Pathol 1994;30(11):1367–1372.

    Article  Google Scholar 

  44. Broaddus WC, Liu Y, Steele LL, et al. Enhanced radiosensitivity of malignant glioma cells after adenoviral p53 transduction. J Neurosurg 1999;91(6):997–1004.

    Article  CAS  PubMed  Google Scholar 

  45. Sakakura C, Sweeney EA, Shirahama T, et al. Overexpression of bax sensitizes human breast cancer MCF-7 cells to radiation-induced apoptosis. Int J Cancer 1996;67(1):101–105.

    Article  CAS  PubMed  Google Scholar 

  46. Brachman DG, Becket M, Graves D, et al. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cells lines. Cancer Res 1993;53:3667–3669.

    CAS  PubMed  Google Scholar 

  47. Slichenmyer WJ, Nelson WG, Slebos RJ, et al. Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res 1993;53:4164–4168.

    CAS  PubMed  Google Scholar 

  48. Danielsen T, Smith-Sorensen B, Gronlund HA, et al. No association between radiosensitivity and TP53 status, G(1) arrest or protein levels of p53, myc, ras or raf in human melanoma lines. Int J Radiat Biol 1994;75(9):1149–1160.

    Google Scholar 

  49. Nemunaitis J, Swisher SG, Timmons T, et al. Adenovirusmediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol 2000;18(3):609–622.

    CAS  PubMed  Google Scholar 

  50. Schuler M, Herrmann R, De Greve JL, et al. Adenovirusmediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. J Clin Oncol 2001;19(6):1750–1758.

    CAS  PubMed  Google Scholar 

  51. Swisher S, Roth JA, Komaki R, et al. A phase II trial of adenoviral mediated p53 gene transfer (RPR/INGN 201) in conjunction with radiation therapy in patients with localized non-small cell lung cancer (NSCLC). Am Soc Clin Oncol 2000;19:461a.

    Google Scholar 

  52. Peng Z, Han D, Zhang S, et al. Clinical evaluation of safety and efficacy of intratumoral administration of a recombinant adenoviral-p53 anticancer agent (Genkaxin?). Mol Ther 2003;7:422–423.

    Google Scholar 

  53. Ito I, Ji L, Tanaka F, et al. Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo. Cancer Gene Ther 2004;11:733–739.

    Article  CAS  PubMed  Google Scholar 

  54. Uno F, Sasaki J, Nishizaki M, et al. Myristoylation of the FUS1 protein is required for tumor suppression in human lung cancer cells. Cancer Res 2004;64(9):2969–2976.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Thoracic Molecular Oncology, Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Jack A. Roth MD, FACS (Professor and Bud Johnson Clinical Distinguished Chair, Professor of Molecular and Cellular Oncology, Director, WM Keck Center for Innovative Cancer Therapies, Chief)

Authors
  1. Jack A. Roth MD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pathology, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA

    Dani S. Zander MD

  2. Institute of Pathology, Laboratories for Molecular Cytogenetics, Medical University of Graz, Graz, Austria

    Helmut H. Popper MD

  3. Department of Pathology, University of Texas Health Science Center, San Antonio, TX, USA

    Jaishree Jagirdar MD

  4. Weill Medical College of Cornell University, New York, NY

    Abida K. Haque MD

  5. Department of Pathology, San Jacinto Methodist Hospital, Baytown, TX, USA

    Abida K. Haque MD

  6. Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY

    Philip T. Cagle MD  & Roberto Barrios MD  & 

  7. The Methodist Hospital, Houston, TX, USA

    Philip T. Cagle MD  & Roberto Barrios MD  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science+Business Media, LLC.

About this chapter

Cite this chapter

Roth, J.A. (2008). Gene Therapy Approaches for Lung Cancer. In: Zander, D.S., Popper, H.H., Jagirdar, J., Haque, A.K., Cagle, P.T., Barrios, R. (eds) Molecular Pathology of Lung Diseases. Molecular Pathology Library, vol 1. Springer, New York, NY. https://doi.org/10.1007/978-0-387-72430-0_21

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-72430-0_21

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-72429-4

  • Online ISBN: 978-0-387-72430-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation